Avid Bioservices Inc (CDMO)

[biopharm]

Partner prior second look in Couch way too risky for big pharma x to let y grab what might be.

Does anyone think J and J said let's wait for more data on ibrutinib it's only in phase II and only been studied on less then 200 patient.
..
..

I agree MD and the sabotage and new knowledge Peregrine has discovered on how valuable the PS Targeting pipeline actually is...

I'm sure a deal can be made.

I wonder if a mid-size pharma steps up with less cash for Peregrine but offers an amazing deal like 3-5 shares of their stock for every 1 PPHM

Big Pharma can offer 1 for 1 shares and their market cap can double...but a mid-size offering 3..4..or 5 for 1 shares along with cash can probably increase their market cap multiples higher

Some big out of the box thinking can come out of this